Clinical Features and HSCT Outcome for SCID in Turkey

Ikinciogullari A., Cagdas D., Dogu F., Tugrul T., Karasu G., Haskologlu S., ...Daha Fazla

JOURNAL OF CLINICAL IMMUNOLOGY, cilt.39, sa.3, ss.316-323, 2019 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 39 Sayı: 3
  • Basım Tarihi: 2019
  • Doi Numarası: 10.1007/s10875-019-00610-x
  • Dergi Adı: JOURNAL OF CLINICAL IMMUNOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.316-323
  • Van Yüzüncü Yıl Üniversitesi Adresli: Evet

Özet

Severe combined immunodeficiency (SCID) is the most serious PID, characterized by T cell lymphopenia and lack of antigen-specific T cell and B cell immune responses, inevitably leading to death within the first year of life if hematopoietic stem cell transplantation (HSCT) is not performed.